Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Determining the prevalence of MGUS & deciphering the mechanisms of disease progression

Rafat Abonour • 26 Aug 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma
iStopMM PROMISE

Rafat Abonour, MD, Indiana University School of Medicine, Indianapolis, IN, emphasizes the importance of determining the true prevalence of monoclonal gammopathy of undetermined significance (MGUS) and better understanding the mechanisms that lead to the development of multiple myeloma, sharing insights from the iStopMM (NCT03327597) and PROMISE (NCT03689595) studies. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rafat Abonour

1:05
Insights into Connect® MM & the need for better designed clinical trials
Rafat Abonour • 26 Aug 2022
0:59
The MGP panel: a targeted genomics panel to identify cytogenetic abnormalities in multiple myeloma
Rafat Abonour • 26 Aug 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals